Localized prostate cancer: Can we better define who is at risk of unfavourable outcome?

BJU International, Supplement

Volumn 101, Issue SUPPL. 2, 2008, Pages 5-10

  Joniau, Steven ^a   Van Poppel, Hein ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Docetaxel; Prostate cancer; Prostatectomy; Radiotherapy; Risk assessment

Indexed keywords

BICALUTAMIDE; CYPROTERONE; DOCETAXEL; ESTRAMUSTINE; GOSERELIN; LEUPRORELIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; COMORBIDITY; HIGH RISK PATIENT; HORMONE INHIBITION; HUMAN; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 40149105397     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07488.x     Document Type: Review

References (27)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18 : 581 92
2. Tewari A, Johnson C, Divine G et al. Long-term survival probability in men with clinically localised prostate cancer: a case-control, propensity modelling study stratified by race, age, treatment and comorbidities. J Urol 2004 171 : 1513 9
3. Hoedemaeker RF, Vis AN, Van Der Kwast TH. Staging prostate cancer. Microsc Res Tech 2000 51 : 423 9
4. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996 20 : 286 92
5. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006 13 : 57 9
6. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localised prostate cancer. JAMA 2005 293 : 2095 101 SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002 168 : 525 9
7. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
8. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999 17 : 1499 507
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V2, 2007. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/prostate.pdf. Accessed January 2008
10. D'Amico A, Whittington R, Malkowicz S et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localised prostate cancer. JAMA 1998 280 : 969 74
11. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localised prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003 21 : 2163 72. Reprinted with permission from American Society of Clinical Oncology
12. Klotz LH. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. Can J Urol 2005 12 (Suppl. 1 53 7
13. van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998 160 : 1392 7
14. van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008 53 : 253 9
15. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005 95 : 751 6
16. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007 51 : 121 9. 2007 © Reprinted with permission from Elsevier
17. Yamada AH, Lieskovsky G, Petrovich Z, Chen SC, Groshen S, Skinner DG. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994 17 : 277 85
18. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997 32 : 385 90
19. Martínez de la Riva SI, López-Tomasety JB, Marrero Domínguez R, Santamaría Blanco P. Perineal radical prostatectomy as monotherapy: ten-year experience Arch Esp Urol 2004 57 : 397 411
20. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005 366 : 572 8
21. Thompson IM Jr., Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomised clinical trial. JAMA 2006 296 : 2329 35
22. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997 337 : 295 300. 1997 © 1997 Massachusetts Medical Society. All rights reserved
23. McLeod DG, Iversen P, See WA et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006 97 : 247 54
24. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 7 : 472 9
25. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
26. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitroxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
27. Kibel AS, Rosenbaum E, Kattan MW et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007 177 : 1777 81